Summit Therapeutics, Inc., shared on LinkedIn:
“Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit’s Expanding Network of Clinical Collaborations Underscore Confidence in Ivonescimab’s Potential
Ivonescimab Global Clinical Development Program Continues to Grow with New Studies in Bladder and Kidney Cancers
Ivonescimab Regimens Demonstrate Statistically Significant Overall Survival Benefits Versus Pembrolizumab in PD-L1–Positive Advanced NSCLC and Versus Durvalumab Plus Chemotherapy in Biliary Tract Cancer in Akeso’s Phase III Studies Conducted in China
Summit Closes Third Quarter with $629.8 Million in Cash and Investments and Received $2.0 Billion from AstraZeneca in Connection with an Equity Investment Post Third Quarter”
Proceed to the video attached to the post:
Scientific contributions of Summit Therapeutics
- Advancement of ivonescimab: Secured licensing rights to develop and commercialize ivonescimab (SMT112) across the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
- Development of a novel bispecific antibody: Advanced the clinical development of ivonescimab, an investigational therapy designed to simultaneously target PD-1 and VEGF, combining immune checkpoint inhibition with anti-angiogenic activity.
- Expansion of Phase III clinical research: Initiated three major Phase III clinical trials—HARMONi, HARMONi-3, and HARMONi-7—investigating ivonescimab in different non-small cell lung cancer (NSCLC) populations.
- Growing global clinical development: Contributed to the expansion of ivonescimab research, with more than 3,000 patients treated across clinical trials globally, while pursuing its potential application in additional solid tumors.
Read other articles about Summit Therapeutics in OncoDaily
You may also be interested in: